Nectar Lifesciences Sells Menthol Business to Ceph

  Published 11 months ago

Nectar Lifesciences sells menthol business to Ceph for Rs 20 crore as part of restructuring, aiming to focus on innovation and debt repayment.

  • The deal covers APIs and formulations via a slump sale part of a broader business restructuring.
  • Shareholder approval on August 4; expected completion by September 2025.
  • Proceeds to repay debt fund growth, and potentially reward shareholders.

You might like these

Lupin & SUP Partner for Tiotropium DPI in China

Inox Wind Wins 51 MW FEPL Order

IRB Toll Revenue Rises 5% in June

Middle East Tensions Spook Markets, Crude Surges 9%

Indian Market: Steady Start Amid Global Uncertainty

India Extends Cotton Duty-Free Import

RBI Study Reveals Corporate Revival

News that matters the most ⚡